Select publications

Avril A et al. Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancers larger than 3 cm. Chirurgie 1998;123(3):247-56. Abstract

Broet P et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial. Breast Cancer Res Treat 1999;58(2):151-6. Abstract

Danforth DN Jr et al. Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for Stage II breast cancer: A prospective randomized trial. Ann Surg Oncol 2003;10(6):635-44. Abstract

Fisher B et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16(8):2672-85. Abstract

Fisher B et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347(8):567-75. Abstract

Fisher B et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347(16):1233-41. Abstract

Gazet JC et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: Results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 2001;12(5):685-91. Abstract

Jakesz R, for ABCSG. Comparison of pre- vs postoperative chemotherapy in breast cancer patients: Four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 2001;20:125;Abstract 125.

Makris A et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9(11):1179-84. Abstract

Mauriac L et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up. Ann Oncol 1999;10(1):47-52. Abstract

Ragaz J. Emerging modalities for adjuvant therapy of breast cancer: Neoadjuvant chemotherapy. NCI Monogr 1986;1:145-52. Abstract

Ragaz J et al. Neoadjuvant-preoperative-chemotherapy for breast cancer — Preliminary report of the Vancouver trial. Prog Clin Biol Res 1985;201:77-87. No abstract available

Scholl SM et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991;27(12):1668-71. Abstract

Scholl SM et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial. Eur J Cancer 1994 S6;30A(5):645-52. Abstract

Semiglazov VF et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994;5(7):591-5. Abstract

Wolmark N et al. Preoperative chemotherapy in patients with operable breast cancer: Nineyear results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102. Abstract

van der Hage JA et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19(22):4224-37. Abstract

Select publications

Aebi S et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355(9218):1869-74. Abstract

Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998;352(9132):930-42. Abstract

Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998;351(9114):1451-67. Abstract

Gasparini G et al. Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12(3):454-66. Abstract

Levine M. Clinical practice guidelines for the care and treatment of breast cancer: Adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update). CMAJ 2001;164(2):213. No abstract available

Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19(4):972-9. Abstract

Lundin J et al. A web-based system for individualized survival estimation in breast cancer. BMJ 2003;326(7379):29. No abstract available

Nixon AJ et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994;12(5):888-94. Abstract

Olivotto IA et al. Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 1997;15(1):216-22. Abstract

Pedersen L et al. Medullary carcinoma of the breast: Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 1995;31A(13-14):2289-95. Abstract

Ragaz J et al. Adverse impact of lymphangitic and vascular invasion in early breast cancer: Results from the British Columbia breast cancer outcomes unit. Breast Cancer Res Treat 2002;76(42 Suppl 1);Abstract 119.

Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 1996;23(1 Suppl 2):43-50. Abstract

Ravdin PM et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-91. Abstract

Ravdin PM et al. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998;16(2):515-21. Abstract

Sawka C et al. The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. Br J Cancer 1997;75(10):1534-42. Abstract

Senn HJ et al. Comments on the St Gallen consensus 2003 on the primary therapy of early breast cancer. Breast 2003;12(6):569-82. Abstract

Siminoff LA et al. Doctor-patient communication about breast cancer adjuvant therapy. J Clin Oncol 1989;7(9):1192-200. Abstract

Weir L et al. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol 2002;20(7):1793-9. Abstract

Whelan T et al. Helping patients make informed choices: A randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 2003;95(8):581-7. Abstract